FLGT - Fulgent Genetics Stock Jumps 27% After Strong Q2 Results

Fulgent Genetics stocks (NASDAQ:FLGT) rose 27% on Tuesday after the company posted a 56% rise in second-quarter revenues. For the three-month period ended June 30, Fulgent’s revenues rose to $8.4 million USD, up from $5.4 million USD for the same period last year.

The California-based company offers state-of-the-art next-generation sequencing technology to advance the field of genetic testing. Genetic testing is useful for deciphering an individual’s genetic makeup and seeing whether they are at risk of developing Parkinson’s disease. Genetic testing helps to identify whether a patient should be enrolled in clinical trials, and which trials ...